De-Wei Lai | Microbiology | Best Scholar Award

Prof. Dr. De-Wei Lai | Microbiology | Best Scholar Award

Associate Researcher at Taichung Veterans General Hospital, Taiwan

Dr. De-Wei Lai is an accomplished Associate Researcher at the Department of Medical Research, Taichung Veterans General Hospital, Taiwan. With a strong foundation in applied chemistry and immunology, he has dedicated his career to unraveling the complexities of regulatory T cells in diverse pathological conditions. Dr. Lai’s research spans autoimmunity, regenerative medicine, and the tumor microenvironment, with a focus on innovative immunotherapeutic strategies. His expertise integrates modern molecular techniques with natural extracts and traditional Chinese medicine, aiming to develop novel diagnostic and therapeutic solutions. With over 19 SCI/SCIE-indexed publications, 27 editorial appointments, and 16 awards, Dr. Lai has established himself as a leading voice in immunological research. His work, characterized by precision and translational potential, continues to shape the future of immunotherapy.

Professional Profile

Education

Dr. De-Wei Lai completed his undergraduate studies in Applied Chemistry at National Pingtung University, where he developed a deep interest in cellular metabolism and biochemical signaling pathways. He later pursued a Ph.D. in Immunology, focusing on the molecular mechanisms underlying diabetic retinopathy, which culminated in a groundbreaking publication in Circulation Research. His academic journey is marked by excellence in understanding complex immunological pathways and leveraging this knowledge for practical medical applications.

Professional Experience

Dr. Lai began his research career in 2019 at Chang Bing Show Chwan Memorial Hospital, where he studied the isolation, cultivation, and functional analysis of regulatory T cells (Tregs). His work laid the foundation for significant advancements in immunotherapy. In 2024, he joined Taichung Veterans General Hospital, where he expanded his focus to include molecular mechanisms of Tregs in autoimmune diseases, regenerative medicine, and tumor microenvironments. Throughout his career, Dr. Lai has consistently contributed to high-impact research, addressing critical gaps in clinical immunology and advancing innovative therapeutic strategies.

Research Interests

Dr. Lai’s research interests lie at the intersection of immunotherapy, molecular biology, and regenerative medicine. His laboratory explores the molecular mechanisms of regulatory T cells in autoimmune diseases, age-related degenerative conditions, and cancer. Recently, Dr. Lai has extended his work to study the potential of natural extracts, traditional Chinese medicine, and metal-organic nanoparticles as modulators of the immune system. By integrating experimental models with clinical big data, his research aims to develop novel diagnostic tools and immunotherapeutic strategies that address pressing medical challenges.

Research Skills

Dr. Lai possesses a robust skill set in immunological research and molecular biology. His expertise includes regulatory T cell isolation and expansion, animal model development for autoimmune diseases, and the study of tumor microenvironments. He is proficient in advanced techniques such as flow cytometry, immunohistochemistry, and molecular signaling analysis. His interdisciplinary approach also incorporates the evaluation of natural compounds and nanoparticles for therapeutic applications. With strong analytical skills and an eye for innovation, Dr. Lai excels in bridging basic research with translational medicine.

Awards and Honors

Dr. Lai’s contributions to immunological research have been widely recognized. He has received 16 awards and recognitions, highlighting his impact in both academic and clinical settings. These honors reflect his groundbreaking discoveries in T cell biology, innovative therapeutic approaches, and commitment to advancing immunotherapy. His editorial appointments in 27 journals and conferences further underscore his standing in the scientific community as a trusted authority in immunological research. Dr. Lai’s dedication to addressing clinical challenges continues to earn him accolades and inspire future research efforts.

Conclusion

Dr. De-Wei Lai is an excellent candidate for the Best Scholar Award due to his exceptional research achievements, dedication to addressing clinical challenges, and innovative approach to immunotherapy. While he excels in academic publication and editorial roles, areas like project leadership, patents, and international collaborations offer room for growth. Overall, his contributions to immunology and translational medicine make him a strong contender for this recognition.

Publications Top Notes

  • Melatonin set out to ER stress signaling thwarts epithelial mesenchymal transition and peritoneal dissemination via calpain‐mediated C/EBP β and NF κ B cleavage
    • Authors: SM Wu, WY Lin, CC Shen, HC Pan, W Keh‐Bin, YC Chen, YJ Jan, DW Lai, …
    • Journal: Journal of Pineal Research, 60 (2), 142-154
    • Year: 2016
    • Citations: 98
  • Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress, and inhibiting epithelial-to-mesenchymal transition
    • Authors: SH Liu, WJ Lee, DW Lai, SM Wu, CY Liu, HR Tien, CS Chiu, YC Peng, …
    • Journal: Molecular Oncology, 9 (4), 834-849
    • Year: 2015
    • Citations: 64
  • Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model
    • Authors: HC Pan, DW Lai, KH Lan, CC Shen, SM Wu, CS Chiu, KB Wang, …
    • Journal: Carcinogenesis, 34 (11), 2568-2579
    • Year: 2013
    • Citations: 45
  • Aryl hydrocarbon receptor deficiency attenuates oxidative stress-related mesangial cell activation and macrophage infiltration and extracellular matrix accumulation in diabetic nephropathy
    • Authors: WJ Lee, SH Liu, CK Chiang, SY Lin, KW Liang, CH Chen, HR Tien, …
    • Journal: Antioxidants & Redox Signaling, 24 (4), 217-231
    • Year: 2016
    • Citations: 44
  • The novel Aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination
    • Authors: DW Lai, SH Liu, AI Karlsson, WJ Lee, KB Wang, YC Chen, CC Shen, …
    • Journal: Oncotarget, 5 (17), 7788
    • Year: 2014
    • Citations: 43
  • Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways
    • Authors: CS Chiu, CH Tsai, MS Hsieh, SC Tsai, YJ Jan, WY Lin, DW Lai, SM Wu, …
    • Journal: Cancer Letters, 442, 113-125
    • Year: 2019
    • Citations: 42
  • TPL2 (therapeutic targeting tumor progression locus-2)/ATF4 (activating transcription factor-4)/SDF1α (chemokine stromal cell-derived factor-α) axis suppresses diabetic retinopathy
    • Authors: DW Lai, KH Lin, WHH Sheu, MR Lee, CY Chen, WJ Lee, YW Hung, …
    • Journal: Circulation Research, 121 (6), e37-e52
    • Year: 2017
    • Citations: 37
  • Attenuation of in vitro and in vivo melanin synthesis using a Chinese herbal medicine through the inhibition of tyrosinase activity
    • Authors: SC Liu, ML Sheu, YC Tsai, YC Lin, CW Chang, DW Lai
    • Journal: Phytomedicine, 95, 153876
    • Year: 2022
    • Citations: 22
  • Melatonin protects retinal integrity through mediated immune homeostasis in the sodium iodate-induced mouse model of age-related macular degeneration
    • Authors: LC Ku, ML Sheu, HH Cheng, CY Lee, YC Tsai, CY Tsai, KH Lin, LC Lai, …
    • Journal: Biomedicine & Pharmacotherapy, 161, 114476
    • Year: 2023
    • Citations: 10
  • AHR/TET2/NT5E axis downregulation is associated with the risk of systemic lupus erythematosus and its progression
    • Authors: HH Cheng, L Hung‐Ke, ML Sheu, CY Lee, YC Tsai, DW Lai
    • Journal: Immunology, 168 (4), 654-670
    • Year: 2023
    • Citations: 8

 

Nazila Bahmaie | Immunology and Microbiology | Best Researcher Award

Dr. Nazila Bahmaie | Immunology and Microbiology | Best Researcher Award

clinical research assistant at Ankara Yildirim Beyazit University, Turkey

Nazila Bahmaie is a dedicated researcher and PhD candidate specializing in Cancer Biology. Born in Ahvaz, Iran, on December 21, 1990, she has pursued an academic and research career across multiple countries, including Iran, Cyprus, and Turkey. Currently enrolled at Ankara Yildirim Beyazit University in Turkey, Nazila is focused on advancing her expertise in cancer biology. Her international academic experience has allowed her to engage with diverse research methodologies, enhancing her scientific adaptability. With a deep commitment to biomedical research, she aims to contribute to groundbreaking discoveries in cancer treatment and immunology. Nazila’s extensive background in medical sciences reflects her passion for understanding complex biological processes and her dedication to improving global healthcare outcomes.

Professional Profile

Education

Nazila Bahmaie has an impressive academic background, with degrees in cellular and molecular biology, medical microbiology, and immunology. She completed her BSc in Cellular and Molecular Biology, majoring in Microbiology, at Maragheh University in Iran, followed by an MSc in Medical Microbiology and Immunology at Zanjan University of Medical Sciences, where she graduated with distinction. Continuing her academic journey, she pursued a PhD in Immunology and Allergy at Near East University in Cyprus before transferring to her current PhD program in Cancer Biology at Ankara Yildirim Beyazit University in Turkey. Her educational trajectory demonstrates a consistent focus on biology and medical sciences, with an emphasis on translational research that bridges basic science and clinical applications.

Professional Experience

Nazila Bahmaie’s professional journey includes significant research roles in cancer biology, immunology, and medical microbiology. As a PhD candidate at Ankara Yildirim Beyazit University, she conducts cancer research under the guidance of prominent scientists, focusing on cancer biology and immunological mechanisms. Before this, she contributed to the field of immunology during her PhD fellowship at Near East University, where she explored pediatric immunology and allergy. Nazila has also worked in medical microbiology, conducting essential research during her MSc studies at Zanjan University of Medical Sciences. Her professional experiences have equipped her with diverse research skills, including cellular and molecular techniques, and a deep understanding of immune responses in diseases.

Research Interests

Nazila Bahmaie’s research interests are focused on the intersection of cancer biology and immunology, particularly in understanding the molecular mechanisms that drive cancer progression and how the immune system can be leveraged to treat cancers. She is deeply involved in studying the immune responses in cancer patients and exploring innovative immunotherapy approaches that could lead to more effective treatments. Her background in microbiology also informs her interest in how microbial infections can influence immune regulation and cancer development. Nazila aims to contribute to the development of targeted therapies that enhance the body’s immune response against tumors, making her research both translational and clinically relevant.

Awards and Honors

Nazila Bahmaie has consistently excelled throughout her academic career, earning high honors and recognition for her academic performance. She graduated with distinction during her MSc in Medical Microbiology and Immunology, earning an A++ for her academic achievements at Zanjan University of Medical Sciences. In addition, she successfully secured a PhD fellowship in Immunology and Allergy at Near East University, showcasing her dedication and merit in the field. While specific awards and honors related to her current PhD work are not detailed, her academic trajectory and continuous involvement in research highlight her potential for future recognition in the scientific community, particularly in cancer biology and immunology.

Conclusion

Nazila Bahmaie has a solid academic foundation and promising potential, particularly in the fields of cancer biology and immunology. However, to be a strong contender for the Best Researcher Award, she would benefit from expanding her publication portfolio, demonstrating a clear impact of her research, and engaging in leadership roles. If she addresses these areas, she could emerge as a notable candidate in future award cycles.

Publication top noted

  • 📄 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study)
    • Authors: Daneshi, N., Esmaeilzadeh, A., Bahmaie, N.
    • Journal: Eurasian Journal of Medicine
    • Year: 2022
    • Citations: 1
  • 📄 Cell-Free Treatments: A New Generation of Targeted Therapies for Treatment of Ischemic Heart Diseases
    • Authors: Daneshi, N., Bahmaie, N., Esmaeilzadeh, A.
    • Journal: Cell Journal
    • Year: 2022
    • Citations: 3
  • 📄 Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study
    • Authors: Esmaeilzadeh, A., Bahmaie, N., Nouri, E., Hajkazemi, M.J., Rafie, M.Z.
    • Journal: International Journal of Molecular Sciences
    • Year: 2021
    • Citations: 8
  • 📄 The Clinical Efficacy of Rituximab Administration in Autoimmunity Disorders, Primary Immunodeficiency Diseases and Malignancies
    • Authors: Zian, Z., Berry, S.P.D.-G., Bahmaie, N., Khan, H., Azizi, G.
    • Journal: International Immunopharmacology
    • Year: 2021
    • Citations: 5
  • 📄 Clinical Applications of Interleukin-37: A Key Player in the Immunopathogenesis of Immune Disorders
    • Authors: Khosh, E., Bahmaie, N., Elahi, R., Esmaeilzadeh, A.
    • Journal: Iranian Journal of Allergy, Asthma and Immunology
    • Year: 2020
    • Citations: 2